Welcome to our dedicated page for Can-Fite BioPharma Ltd. SEC filings (Ticker: CANF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Can-Fite BioPharma Ltd. filings document foreign-private-issuer disclosures for a clinical-stage biotechnology company whose American Depositary Shares trade under CANF. Its Form 6-K reports furnish press releases, annual and special meeting materials, proxy statements, voting instruction cards for ADS holders, and shareholder-vote results.
The company’s regulatory record covers clinical and regulatory updates for A3AR drug candidates, Namodenoson and Piclidenoson patent matters, partner-related development disclosures, operating and financial results, capital-structure items, registration-statement incorporation for Form S-8 and Form F-3 filings, governance matters, and risks connected to drug development and public-company financing.
Can-Fite BioPharma Ltd. (CANF) reports a peer-reviewed case describing a patient with advanced decompensated liver cirrhosis treated with its drug candidate Namodenoson, who showed resolution of ascites, regression of esophageal varices, and remained clinically stable for approximately 28 months before a successful liver transplant in January 2026. The treating physician noted that improvements in portal-hypertension complications occurred despite continued deterioration in hepatic synthetic function and viewed the case as supporting further evaluation of Namodenoson in advanced liver disease. Namodenoson, an A3 adenosine receptor agonist, is already in a pivotal Phase 3 trial for hepatocellular carcinoma and a Phase 2b trial for MASH, and has Orphan Drug Designation in the U.S. and Europe and Fast Track status from the FDA for second-line HCC.
Can-Fite BioPharma Ltd. (CANF) is filing a post‑effective amendment on Form F‑1 to update and combine prior registration statements for the resale of 67,880 ordinary shares represented by 33,940 ADSs, all issuable upon exercise of placement agent warrants from its January 2023 and July 2025 financings. The filing covers only shares underlying warrants that remain unexercised and states that no additional securities are being registered beyond those in the prior registration statements and all related filing fees were previously paid. The company will not receive proceeds from selling shareholders’ resales, but may receive up to approximately $0.7 million from cash exercises of January 2023 placement agent warrants and approximately $0.4 million from cash exercises of remaining July 2025 warrants, which it currently plans to use for research and development, general and administrative expenses, and working capital. Ordinary shares outstanding were 6,063,093 as of September 6, 2026; this is a baseline figure, not the amount being offered.
Can-Fite BioPharma Ltd. (CANF) filed a post-effective amendment on Form F-1 that combines and updates two prior resale registration statements, covering up to 67,880 ordinary shares represented by 33,940 ADSs issuable upon exercise of placement agent warrants from its January 2023 and July 2025 financings. The registered securities are being offered for resale by existing selling shareholders; no ADSs are being sold by Can‑Fite itself.
Can‑Fite will not receive proceeds from any resale, but may receive up to roughly $0.7 million from January 2023-related warrants and $0.4 million from July 2025 warrants if they are exercised for cash. As of September 6, 2026, 6,063,093 ordinary shares were outstanding, with significant additional ordinary shares underlying options and warrants, indicating a sizable potential equity overhang. The prospectus highlights elevated dilution and market‑price pressure risk from warrant exercises and resales, and details extensive geopolitical risks tied to operating from Israel.
Can-Fite BioPharma Ltd. (CANF) reported first-half 2026 results showing continued clinical progress alongside ongoing losses and a modest cash base. For the six months ended June 30, 2026, revenues were $0.20 million, research and development expenses rose to $3.46 million, general and administrative expenses fell to $1.43 million, and net loss was $4.60 million versus $4.88 million a year earlier.
As of June 30, 2026, Can-Fite held $7.03 million in cash, cash equivalents and short-term deposits and had an accumulated deficit of about $180.8 million. Operating cash outflow was $5.31 million in the period. Management evaluated going-concern conditions and, based on cost-control and reprioritization plans, concluded these actions alleviate substantial doubt for at least 12 months, while still expecting the need for significant additional financing to advance its pipeline.
Clinically, Namodenoson’s Phase IIa pancreatic cancer study achieved its primary safety endpoint with durable survival outcomes, and a Phase IIb chemo-combination protocol is in development. In advanced hepatocellular carcinoma, blinded overall survival in the pivotal Phase III Namodenoson study appears longer than originally anticipated, prompting consideration of an earlier interim analysis. Piclidenoson’s pivotal Phase 3 psoriasis trial has reached its pre-specified interim analysis stage, with results expected in early 2027. Can-Fite also expanded patent coverage for Namodenoson and Piclidenoson in multiple territories and completed warrant-inducement transactions in March and September 2026 providing approximately $8 million in gross proceeds.
Can-Fite BioPharma Ltd. (CANF) entered into an inducement agreement with an existing warrant holder, who agreed to exercise for cash 1,591,738 ADSs at a reduced exercise price of $2.50 per ADS, instead of the original $5.00, in exchange for new warrants.
The company expects approximately $4.0 million in gross proceeds, before a 7.0% placement fee, a 1.0% management fee, and additional fixed expenses. In consideration, Can-Fite will issue new warrants for up to 3,183,476 ADSs at $2.50 per ADS and Placement Agent Warrants for 111,422 ADSs at $3.125 per ADS, all privately placed under a Section 4(a)(2) exemption.
The new and Placement Agent Warrants are immediately exercisable for two years from the effective date of a resale registration statement that Can-Fite plans to file and seek to have declared effective within 90 days. The company agreed to a 30‑day restriction on most new equity issuances and registrations and a one‑year restriction on Variable Rate Transactions, and intends to use net proceeds for research and development, clinical trials, and general corporate purposes.
Can-Fite BioPharma Ltd. (CANF) entered into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to 1,591,738 American Depositary Shares (ADSs). The warrants, originally issued in March 2026 with an exercise price of $5.00 per ADS, will be exercised at a reduced price of $2.50 per ADS, under an effective Form F-3 registration statement. The transaction is expected to generate approximately $4.0 million in gross proceeds, with closing expected on or about September 3, 2026, subject to customary conditions.
In consideration for the cash exercise, Can-Fite will issue new unregistered warrants to purchase up to 3,183,476 ADSs at an exercise price of $2.50 per ADS, immediately exercisable until the twenty-four month anniversary of the effective date of a planned Resale Registration Statement. The company states it intends to use the net proceeds to fund research and development, clinical trials, and for other working capital and general corporate purposes.
Can-Fite BioPharma Ltd. (CANF) reported that blinded overall survival in its ongoing pivotal Phase III study of Namodenoson in advanced hepatocellular carcinoma appears longer than originally anticipated versus the assumptions used in the study design. The randomized, double-blind, placebo-controlled trial enrolls patients with advanced HCC and underlying Child-Pugh B7 cirrhosis, with overall survival as the primary endpoint.
The current observation is based on pooled, blinded data from both Namodenoson and placebo arms, so no efficacy conclusions or between-arm differences can be drawn at this stage. In response to the longer-than-anticipated survival, Can-Fite plans to evaluate an earlier timing for the study’s planned interim analysis, which will allow an independent assessment of overall survival between treatment groups under the predefined statistical analysis plan and regulatory requirements.
Can-Fite BioPharma Ltd. (CANF) filed a Form F-3 shelf registration to offer, issue and sell from time to time up to $100,000,000 of securities, including ordinary shares (and ADSs), warrants, subscription rights and units. A separate Offering Agreement prospectus supplement will govern an at-the-market program, whose ADS sales are included within this $100,000,000 capacity.
ADSs trade on NYSE American under “CANF” and ordinary shares on the TASE under “CANF”; each ADS represents two ordinary shares. As of July 1, 2026, public float was about $9.9 million, limiting primary sales under Form F-3 to one-third of that amount in any 12-month period, of which approximately $2.2 million has already been sold. Can-Fite is a clinical-stage biopharmaceutical company developing oral A3 adenosine receptor–targeting drugs, with lead candidates Piclidenoson and Namodenoson in late-stage trials for psoriasis, liver cancer and MASH. The company has effected a 1-for-3,000 reverse split of its ordinary shares and a related 1-for-20 reverse ADS split in January 2026.
Can-Fite BioPharma Ltd. reported new preclinical findings showing that its drug namodenoson enhances the anti-cancer effect of gemcitabine chemotherapy in pancreatic cancer by increasing cleaved caspase-3–mediated apoptosis. These data provide mechanistic support for a planned randomized Phase IIb study in advanced pancreatic adenocarcinoma combining namodenoson with gemcitabine and nab-paclitaxel, following favorable safety and activity seen in a Phase 2a study. Clinical results from the Phase 2a trial have been accepted for presentation at the ESMO Congress 2026. Namodenoson is also in a pivotal Phase 3 trial for advanced liver cancer and a Phase 2b trial for MASH, while lead candidate piclidenoson is in Phase 3 for psoriasis and CF602 targets erectile dysfunction, with an overall clinical safety database of more than 1,600 patients.
Can-Fite BioPharma Ltd. reports that its two lead oral A3 adenosine receptor agonists, Namodenoson and Piclidenoson, are both in Phase III development under regulatory frameworks agreed with the FDA and EMA, providing defined pathways toward potential marketing applications.
Namodenoson is in a pivotal Phase III trial for hepatocellular carcinoma (HCC) in patients with Child-Pugh B7 cirrhosis and holds FDA Fast Track status plus Orphan Drug Designation in both the U.S. and Europe as a second-line HCC treatment. Piclidenoson is in a Phase III program for moderate-to-severe plaque psoriasis. The company also advances Namodenoson in Phase 2b for MASH and Phase 2a in pancreatic cancer, and has a third candidate, CF602, for erectile dysfunction. Across its programs, Can-Fite reports clinical experience in over 1,600 patients, supporting an established safety profile.